Your browser doesn't support javascript.
loading
Measuring disability in amyotrophic lateral sclerosis/motor neuron disease: the WHODAS 2.0-36, WHODAS 2.0-32, and WHODAS 2.0-12.
Young, Carolyn A; Ealing, John; McDermott, Christopher J; Williams, Tim L; Al-Chalabi, Ammar; Majeed, Tahir; Talbot, Kevin; Harrower, Timothy; Faull, Christina; Malaspina, Andrea; Annadale, Joe; Mills, Roger J; Tennant, Alan.
Affiliation
  • Young CA; Walton Centre NHS Foundation Trust, Lower Lane, Liverpool, UK.
  • Ealing J; Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
  • McDermott CJ; Department of Neurology, Greater Manchester Centre for Clinical Neurosciences, Salford, UK.
  • Williams TL; Sheffield Institute for Translational Neuroscience, Sheffield, UK.
  • Al-Chalabi A; Department of Neurology, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
  • Majeed T; Department of Basic and Clinical Neuroscience, King's College London, Maurice Wohl Clinical Neuroscience Institute, London, UK.
  • Talbot K; Department of Neurology, King's College Hospital, London, UK.
  • Harrower T; Department of Neurology, Lancashire Teaching Hospital, Preston, UK.
  • Faull C; Department of Neurology, University of Oxford, Oxford, UK.
  • Malaspina A; Exeter Medical School, University of Exeter, Exeter, UK.
  • Annadale J; LOROS Hospice, Leicester, UK.
  • Mills RJ; UCL Queen Square Institute of Neurology, London, UK.
  • Tennant A; Hywel Dda University Health Board, Wales, UK, and.
Article in En | MEDLINE | ID: mdl-35876069
ABSTRACT

Aim:

To investigate whether the World Health Organization Disability Assessment Schedule 2.0 (WHODAS) can provide interval level measurement of disability in Amyotrophic Lateral Sclerosis (ALS), allowing parametric analyses.

Methods:

Data on the WHODAS 12, 32, and 36-item versions, from 1120 patients studied at one or more time points, were fit to the Rasch model and comparisons made against ALSFRS-R, King's staging, and mortality. Trajectory modeling was undertaken for a newly diagnosed (≤6 months) cohort of 454 individuals.

Results:

Total scores for WHODAS 32 and 36-item versions can be converted to interval level measurement suitable for individual clinical use, and the 12-item WHODAS total for group use. The 36-item version is shown to be equivalent to the 32-item version. Expected correlations were seen with King's staging, ALSFRS-R, and EQ-5D-5L. Trajectory analysis of disability (WHODAS 2.0) showed three clearly demarcated groups with differences in King's staging, depressive symptomatology and mortality, but not age.

Conclusions:

The WHODAS 2.0 is a brief patient reported outcome measure which can be used to measure disability in ALS. Provided the patient answers all 36 (32 if not working) items, the conversion table produces an interval level estimate for parametric analyses. The different trajectories demonstrated from diagnosis support the concept of a prodromal period, and suggest the WHODAS 2.0 could be used for surveillance of at risk populations, such as those with genetic predisposition.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Disabled Persons / Amyotrophic Lateral Sclerosis Type of study: Prognostic_studies Aspects: Patient_preference Limits: Humans Language: En Journal: Amyotroph Lateral Scler Frontotemporal Degener Year: 2023 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Disabled Persons / Amyotrophic Lateral Sclerosis Type of study: Prognostic_studies Aspects: Patient_preference Limits: Humans Language: En Journal: Amyotroph Lateral Scler Frontotemporal Degener Year: 2023 Document type: Article Affiliation country: